Research shows biomarker testing reduces lung cancer deaths by 40% in smokers.
A new groundbreaking study from the University of St Andrews has shown that using biomarker testing in smokers and former smokers significantly reduces deaths related to lung cancer. This research, involving 12,000 participants, demonstrated a 40% reduction in deaths from lung cancer and other causes within a five-year period. The findings highlight the potential of early detection through biomarker testing, offering a promising step forward in combating one of the most deadly cancers worldwide.
Biomarkers are measurable indicators in the body, such as proteins or other substances found in blood or urine, that can reveal changes related to disease. In this study, these markers helped identify individuals at high risk of developing lung cancer, allowing for earlier intervention and better outcomes. Often referred to as a “liquid biopsy,” biomarker testing is a non-invasive method that provides critical insights into a person’s health before symptoms become apparent.
Lung cancer is notorious for being diagnosed at advanced stages, which makes treatment less effective. Each year, around 2 million people worldwide are diagnosed with this disease, and 1.76 million die from it. Despite advancements in treatments, late-stage diagnosis remains a significant hurdle. By pinpointing high-risk individuals early, biomarker testing has the potential to save countless lives by ensuring timely and targeted treatment.
Professor Frank Sullivan, who led the research team, emphasized the importance of early detection in improving survival rates. He noted that the combination of biomarker testing and advanced imaging techniques provides a much better chance of catching lung cancer when it is still treatable. Early diagnosis, paired with today’s improved treatments, can dramatically improve outcomes for patients.

The study’s findings also suggest that incorporating biomarker testing into national screening programs could make these initiatives more effective. Current screening methods often face challenges, such as identifying who should be tested and managing limited resources. By using biomarkers to focus on those most at risk, health systems could use their resources more efficiently while improving results.
Beyond reducing deaths, biomarker testing could also ease the burden on healthcare systems by catching lung cancer earlier, when treatments are less intensive and more successful. The approach not only benefits individuals but could also lower overall treatment costs by avoiding expensive interventions for advanced cases.
This research adds to growing evidence that biomarker testing can play a vital role in fighting lung cancer. While imaging techniques like CT scans are already used for screening, they are not without limitations. Biomarker testing offers a complementary approach, helping to identify cases that might otherwise go unnoticed and ensuring that imaging is used for the right patients.
The study has opened new doors for improving lung cancer care and has laid the groundwork for further research. Experts believe that the lessons learned from this trial could extend to other types of cancer, paving the way for more personalized and effective treatment strategies across the board.
The results are a reminder of the importance of innovation in healthcare. As countries around the world work to address the challenges posed by lung cancer, advancements like biomarker testing provide a path toward better outcomes for patients. By prioritizing early detection and targeted care, we can move closer to a future where fewer people lose their lives to this devastating disease.
Sources:
Lung cancer trial reveals 40% drop in deaths using biomarker testing
Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening
Join the conversation!